Ads
related to: gsk vaccine for rsv- High Risk Patient Types
Learn how SYNAGIS® helps
high risk patient types
- Request a Rep
Contact a rep for SYNAGIS®
additional information
- Prescribing Information
Find prescribing information
for SYNAGIS®
- Access SYNAGIS®
See if your patients are eligible
for our copay program
- High Risk Patient Types
Search results
Results From The WOW.Com Content Network
The trial testing the immune response of co-administration of GSK's blockbuster vaccines, Shingrix and Arexvy, in adults over 50 years of age, met the main goal of the study. The co-administration ...
(Reuters) -The U.S. Food and Drug Administration approved the expanded use of GSK's respiratory syncytial virus (RSV) vaccine on Friday in adults aged between 50 and 59, making it the first shot ...
(Reuters) -GSK shares fell as much as 7% on Thursday, a day after a U.S. public health agency narrowed its age recommendation for use of respiratory syncytial virus (RSV) vaccines and did not ...
The Food and Drug Administration on Wednesday approved the world's first RSV vaccine: a shot for adults ages 60 and up, made by pharmaceutical giant GSK. The milestone was decades in the making .
A respiratory syncytial virus vaccine, or RSV vaccine, is a vaccine that protects against respiratory syncytial virus. [1] RSV affects an estimated 64 million people and causes 160,000 deaths worldwide each year. [2] The RSV vaccines Arexvy , [3] Abrysvo , [4] and Mresvia [5] are approved for medical use in the United States.
Last year, GSK and Pfizer went head-to-head with rival RSV shots for all adults aged 60 and over, who could get the vaccine after consulting a healthcare provider.
Ads
related to: gsk vaccine for rsv